RLX Technology Inc. (RLX) Earnings Call Transcript & Summary
August 20, 2021
Earnings Call Speaker Segments
Sam Tsang
executiveMany thanks. Greetings, everyone, and it's a pleasure to have you join RLX Technologies' conference call covering our earnings for the second quarter of 2021. Earlier today, the company's operational and financial results went out via PR Newswire services and are now accessible online. You may also review the earnings press release by going to the IR section on our site, ir.relxtech.com. Joining us on this call are our Co-Founder, Chairperson of the Board of Directors and Chief Executive Officer, Ms. Kate Wang; our Chief Financial Officer, Mr. Chao Lu; and me, Sam Tsang, Head of Investor Relations. Prior to proceeding, kindly be aware that this discussion includes forward-looking statements issued under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements commonly feature terms like may, will, expect, targets, estimate, intends, believe, potential, continues, or comparable expressions. Inherent risks and uncertainties are part of forward-looking statements. A variety of business risks and uncertainties, many beyond our control, could affect how accurate these statements turn out to be, causing actual results to differ materially from what was projected or anticipated. Neither the company nor its affiliates, advisers, representatives and underwriters accept any duty to refresh this forward-looking information, unless the applicable law requires it. Kindly note that RELX Technologies' earnings press release along with this conference call cover discussions of unaudited GAAP financial measures, and also unaudited non-GAAP financial measures. Within RLX Technologies' press release, you will find a reconciliation of the unaudited non-GAAP measures against the unaudited GAAP measures. At this point I'll hand things over to Ms. Kate Wang. Please go ahead.
Wang Ying
executiveThanks, Sam. Hi, everybody. I appreciate your presence on today's earnings conference call. Most of you know that during the period surrounding the second quarter of 2021, two significant regulatory events occurred. The initial one came on March 22, when officials issued a notice inviting comments from the public regarding our suggested amendments to pertinent rules, aimed at tightening oversight of e-cigarettes and addressing quality and safety concerns, enforcement issues in advertising, and other matters. In our view, this kind of regulatory structure is essential and advantageous for the industry's sustained sound growth over time. It works to remove the dangers tied to ambiguities about whether this product category is legitimate. It also assists in preventing the kinds of occurrences and reverses seen in certain other markets abroad, and in safeguarding the industry's enduring vigor within China. Up to now, nothing specific about the regulatory structure has come out; we intend to keep a close watch and stay updated on any upcoming notices. The subsequent event happened across May and June, when the Chinese National Health Commission released the China report on Health Hazards of Smoking 2020, which brought up vaping products. The press, the general public, and a number of adult smokers and adult users of vaping products found themselves perplexed by particular historical details taken out of context within that report concerning the harm reduction advantages of using vaping products. Adverse coverage has continued ever since that report came out. We've been focusing intently on the pertinent scientific studies and dialogue with consumers to supply improved information and impartial understanding on these subjects. RELX came into being to serve adult smokers through cutting-edge offerings and a steadfast commitment to scientific progress so as to bring harm reduction advantages to those who use our products. Toward that aim, throughout the second quarter, we kept allocating resources toward essential operational domains, such as science, research and development, product innovation, quality of firms and control, and brand building. In addition, being a publicly traded entity, we have reinforced our operational and financial internal controls even more, so as to safeguard shareholder value more effectively. During the second quarter, we kept up our pace in drawing in and cultivating top-tier talent, expanding our workforce by 27%; these extremely capable people came to us from premier businesses spanning FMCG, technology, and pharmaceutical sectors. It's a pleasure to witness such compatible talent becoming part of our journey. And collectively, we've recorded a satisfying net revenue increase of 6%, rising from RMB 2.4 billion in the first quarter to RMB 2.54 billion in the second quarter. Having said that, I'll hand the call over now to our CFO, Lu Chao. He'll share more detail on certain initiatives undertaken in previous quarters and walk through our operational and financial outcomes more thoroughly. Chao, the floor is yours.
Chao Lu
executiveThank you, Kate — and hello, everyone. Being part of RELX has brought me genuine happiness and pride for over a quarter now. Steve Jobs said it well: real satisfaction comes only from doing work you consider excellent. At RELX, that is exactly the kind of work we do — we give adult smokers products built to the highest quality and safety benchmarks, which helps lower harm both for those users and for those around them. It is a privilege to share in this mission. Now I'd like to walk through some specifics of what we did in the second quarter. After that, I'll take you through our financial performance. During the last quarter, we kept growing our offline distribution network and retail channels, even though branded stores showed some softness in product procurement during the latter half of the quarter — most likely a result of negative press coverage of the e-vapor sector and a lack of regulatory clarity. Our strong conviction is that steadily growing our distribution network and retail channel is essential for long-term growth and competitiveness; we are hopeful that as time passes and the publicity effects fade, per-store procurement at branded stores will quickly recover its momentum. When it comes to products, we have concentrated on innovation in both devices and flavors. A substantial pipeline of product offerings is in development, aimed at serving different user groups whose preferences and price sensitivity vary. We anticipate rolling out these offerings in stages, which should further boost penetration and improve user retention. We also take great pride in our reputation, continually delivering top-quality products and investing significantly in strengthening quality control measures, as we aim to further raise the user experience and foster stronger user loyalty; throughout all of our production cycles we carry out stringent quality assurance and control, and we have built 3 production plants to further reinforce our QA and QC capabilities. When it comes to quality assurance and quality control, we have five labs running 197 different checks, which makes sure every batch of aerosol we take in provides the safest and highest-quality vaping experience we can offer. At this point, more than 110 experts manage our entire QC operation, from raw materials through production all the way to finished goods. As for our scientific work, on July 3, 2021, we worked with Sun Yat-sen University to get a research paper published in the SCI Journal, Ecotoxicology and Environmental Safety, and the title is, comparison of biological and transcriptomic effects of conventional cigarettes and electronic cigarette smoke exposure at toxicological dose in BEAS-2B cells. The research table indicated that when nicotine levels are comparable and exposure is acute, condensates from cigarette smoke have a significantly stronger effect on cells and gene expression patterns than those from e-cigarette vapor do, which provides additional proof that e-vapor products reduce harm compared with combustible cigarettes. On August 4, 2021, we achieved successful registration of our e-vapor clinical trial with the China clinical trial registration center as well as the WHO international clinical trial registration platform. This trial of ours is the first e-vapor clinical research effort in China to have passed both ethical and expert reviews and to have been approved for implementation, thus filling a domestic gap in e-vapor clinical research. It also constitutes a pioneering scientific undertaking in China's e-vapor industry. Looking ahead, we'll keep putting money into our own lab research. That covers product quality and safety, physiochemistry, pathological and clinical areas, and how e-vapor products perform when used over the long term. We're devoted to corporate social responsibility, and we remain committed to building and strengthening our trusted brands by sticking firmly to strong ethical standards. On June 1, immediately after the minor protection law went into force, RELX was the first company among all our rivals to call on every player in the industry to carefully review the regulation and follow all of it to the letter. In July, severe weather and natural calamities hit multiple provinces throughout China, which affected hundreds of charitable organizations; we responded quickly again, donating millions to the China Suiyang Foundation for poverty alleviation through an emergency filing; in addition, we were deeply worried about the damage suffered by our partners and decided to set up relief funds for Hunan RELX stores to help them get their businesses back on track. Let's turn now to our financial results. Due to the external elements Kate discussed earlier, our revenue growth from one quarter to the next slowed down in Q2. It is difficult to predict what these factors will lead to, and they might continue past the second quarter as well. Even so, we remain dedicated to making steady progress in how many adult smokers we reach. We firmly believe that the science behind harm reduction, along with its benefits, will win out over mistaken beliefs and inaccurate claims. Now I'll walk through a brief summary of how we performed financially in Q2 2021. Our net revenues climbed 6%, reaching RMB 2.54 billion in the second quarter of 2021, up from RMB 2.4 billion in Q1 2021. The main factor behind this increase was greater net revenues generated through sales to off-line distributors, which stemmed in large part from the company broadening its distribution and retail network. In Q2 2021, gross profit rose 3.8%, reaching RMB 1.15 billion, up from RMB 1.1 billion in Q1 2021. The gross margin was basically unchanged, coming in at 45.1% for the second quarter of 2021 compared with 46% for the first quarter of 2021. Operating expenses came to RMB 167.2 million in Q2 2021, which represents an 86.3% decrease from RMB 1.22 billion in Q1 2021. The main reason for this big reduction in operating expenses was that we recorded share-based compensation of positive RMB 172.5 million, which breaks down into three parts: first, positive RMB 51.5 million of share-based compensation recorded under selling expenses; second, positive RMB 41.4 million of share-based compensation recorded under general and administrative expenses; and third, positive RMB 79.7 million of share-based compensation recorded under research and development expenses. The large fluctuations in share-based compensation costs were driven primarily by shifts in the fair value of the share incentive awards the company granted to employees, and those shifts were influenced by significant movements in the company's share price. During Q2 2021, selling expenses dropped 56.8%, coming in at RMB 126 million, compared with RMB 291.5 million in Q1 2021. Two factors primarily accounted for that decrease: first, shifts in share-based compensation expenses, and second, lower salaries and welfare benefits, which were partly counterbalanced by higher branding material expenses. For general and administrative expenses, the figure declined 93.5% to RMB 46.1 million in Q2 2021, down from 712.8% — RMB 712.8 million — in Q1 2021. That reduction stemmed mainly from, firstly, fluctuation in share-based compensation expenses, and secondly, a drop in salaries and welfare benefits, partially offset by greater legal and other consulting fees. In Q2 2021, R&D spending dropped 102.3%, landing at a positive RMB 4.9 million, down from RMB 211.6 million during Q1 2021. Two main factors explain that decrease: first, share-based compensation expenses fluctuated; second, salaries and welfare benefits went down, though higher depreciation and amortization expenses partly counteracted that. Operating income for Q2 2021 reached RMB 979.3 million, versus an operating loss of RMB 111.9 million in Q1 2021. Income tax expense came to RMB 204.2 million in Q2 2021, up from RMB 176.3 million in Q1 2021. That rise largely stemmed from higher taxable income. For the second quarter of 2021, U.S. GAAP net income came to RMB 824.3 million, versus a U.S. GAAP net loss of RMB 267 million in the first quarter of 2021. Non-GAAP net income reached RMB 651.8 million in the second quarter of 2021, up 6.8% from RMB 610.5 million in the first quarter of 2021. In the second quarter of 2021, U.S. GAAP basic and diluted net income per American depository share stood at RMB 0.595 and RMB 0.591, respectively, compared with U.S. GAAP basic and diluted net loss per ADS of RMB 0.174 each in the first quarter of 2021. For the second quarter of 2021, non-GAAP basic net income per ADS came in at RMB 0.47, while the diluted figure was RMB 0.467. In the first quarter of 2021, both non-GAAP basic and diluted net income per ADS stood at RMB 0.398. Turning to the balance sheet, at the close of June 30, 2021, the company held cash and cash equivalents, restricted cash, short-term bank deposits, short-term investments, and long-term bank deposits totaling RMB 14.88 billion. That compares with RMB 14.44 billion on March 31, 2021. Of the June 30, 2021 total, roughly USD 1.64 billion was held in U.S. dollars. That wraps up our prepared remarks for today. We'll now take questions. Operator, please go ahead.
Lydia Ling
analystLydia here, calling in from Citi. Two things I'd like to ask. First, with the softer performance we saw during Q2, can you walk us through how Q3 has been shaping up so far, plus what you expect for the back half of the year, especially with all the negative headlines lately and the regulatory backdrop? Then my second one concerns expansion. Could you share the number of outlets launched during Q2? And what does your rollout blueprint for the back half look like, given where the market stands right now? On top of that, how are distributors feeling about these new launches?
Sam Tsang
executiveSure. Thanks a lot, Lydia. On your first point, it's really about the Q3 trajectory and what we see for the back half. Right now, e-vapor products are still underpenetrated among adults in China. Our company holds the view that harm reduction products, e-vapor included, represent superior options for adult smokers in China. We stay dedicated to the shift of adult smokers away from cigarettes toward e-vapor products, and we have confidence in the medium and long-term prospects of the inventory — of the industry, and in our own future results too; so to answer you directly, on our Q3 trends to date in particular, we've seen operating and financial metrics come back to life over recent weeks as we keep engaging and retaining our users. That leaves us quite confident about what lies ahead for the company. Now on your second point, it's really about store counts, the opening plan, distributor sentiment, and so on; so on our overall logic for opening stores, we think our present model is quite sound. That model mostly hinges on whether there are sufficient users of our products in a given area or district to sustain a brand partner store; so when it comes to newly opened branded partner stores, we track and assess store productivity alongside other macro and micro factors. Take this example: where productivity at newly opened stores beats the expected productivity curve, we'll permit additional new stores to open, and the reverse also applies. We do have various color label packs across different districts or areas, based on how existing stores perform, so we can micromanage and witness or manage any cannibalization between existing and new stores; so yes, we do keep a close eye on the single store economic model of our current brand partner stores. So thanks very much for your question.
Charlie Chen
analystThere are a couple of things I'd like to cover. To start, could you speak to how the products have been performing across the various categories — for instance, the premium offerings compared with the mainstream ones that came out roughly a quarter back? What has the trajectory looked like up to now? Then for my second one, it's about what consumers actually pay at retail. We've noticed the competitive intensity is pretty high in a few segments. Are you picking up on any easing of retail pricing, or maybe more fluctuation, in certain markets? On top of that, are there any unusual cases where distributors engage in parallel trading — meaning they move goods at a cheaper price into territories they aren't authorized for? Is that kind of thing showing up in your market?
Sam Tsang
executiveOkay, many thanks, Charlie. On your first point, it concerns our product lineup. We've kept a diversified portfolio spanning a range of price points, from generic through to features. What you're seeing is a growing number of users — adult smokers across differing user groups — turning to what we offer as their harm reduction option. As for the new items, we are observing favorable feedback along with contributions from users and retailers alike; so we'll keep carefully watching how users behave and what the trends are, working to fine-tune the mix of products while putting out additional product lines; now your second point concerns pricing — the real retail selling price — and whether distributors make unauthorized sales into unauthorized territories; taking pricing first. We've kept a close eye on pricing throughout the value chain, particularly the real selling price and the discounts on our goods as seen from the retailer side. In fact, during the second quarter of 2021, we rolled out a program to track the real selling price at every layer of our value chain. What we're seeing is that the majority of our retailers, above all the branded partner stores, have stuck to the suggested retail selling price when making actual sales to adult smokers. As for distributors making unauthorized sales into unauthorized territories, we've in fact been putting in place effective measures around technology and control. Every one of our product lines carries a unique QR code system. So should any distributor or retailer of ours report instances they come across of unauthorized products showing up, we'd be able to uncover which distributors are behind it, determine which products are involved, and address the problem as needed; so many thanks for your questions.
Stephanie Lam
analystThere are two things I'd like to ask. First, about the subsidy for opening stores. We've seen that a number of competitors have given out bigger opening subsidies over the last few months. So what does management think about this, and what's our own strategy when it comes to opening subsidies? My second question relates to pressure on raw material costs and the gross margin. With raw material costs going up, have we perhaps raised the wholesale prices charged to franchisees and distributors so the cost gets passed along? And how should we think about the margin trend ahead?
Sam Tsang
executiveSure. Many thanks, Stephanie. On the first point, about our subsidies, in light of the competitive landscape, you can see that our store subsidies have stayed steady, and the subsidy we give per store has fallen steadily ever since we launched our branded partner stores model in early 2019; when deciding whether to assess and grant stores, we've done so mainly on the basis of the macro environment and the single store economics of our branded partner stores. So I'd say that over the last 2 years, competitors have given much larger subsidies to people who might become store owners, motivated by their wish to penetrate the market and establish a presence. Yet that high frequency of large subsidies did not turn into market share growth for their brands. With the way the industry is currently developing, we've lately observed competitors beginning to cut back their subsidies to potential branded partner stores. Over the medium and long term, we think stores will behave more rationally and will rely more on the single store economics of each brand's branded partner stores. Now, on the second question, about the rise in raw materials and whether that pushed up our pricing and margins. Given the macro situation, prices for raw materials — chips and batteries, for instance — have trended upward since the year began. Consequently, certain suppliers of ours have seen procurement costs rise across the supply chain. Even so, we haven't actually seen any meaningful rise in unit cost from raw material prices up to now. That's why we haven't raised the wholesale price of the products we sell to our distributors. Naturally, we'll keep a close watch on the newest supply chain developments and on operating issues at our suppliers. With cost optimization efforts across our whole industry value chain — automated production and cost-saving product design, for example — we think the industry's long-term unit cost, ours included, will be optimized even further. Thank you so much for your question.
Junhao Fan
analystThis is Junhao calling in from CICC, and I've got 2 questions as well. To start with, it's clear that e-cigarettes keep showing up on the market in growing numbers. How does management see the competition shaping up down the road among Chinese e-cigarette brands? Then for my second one, given that plenty of comparable vape cartridges are available on the market — ones that can likewise be used in our devices, like wick — what steps would RELX take to address that issue? Those are my 2 questions.
Sam Tsang
executiveThanks so much, Junhao. On your first point, which concerns how competition will look in China's e-vapor markets — our view is that the competitive environment there is going to get more and more complicated, which means every brand or player in the market has to invest greater effort and keep innovating when it comes to things like commercial strategy, product innovation, and scientific research work. With our leading position, solid brand equity, broad retail network, and ability to innovate on products, we're confident we can hold onto or grow our market leadership within China. As for your second question, I want to make sure I heard it right — it's about those compatible parts you brought up. When it comes to unauthorized compatible parts, we genuinely observe that they create a bigger health risk for e-vapor users, since there's no guarantee around product quality and safety. On top of that, such compatible parts tend to be sold through illegal retail channels, which means underage users might be able to get them. As a brand, we've been working alongside various partners and parties to stop illegal sales of unauthorized compatible parts, and we've brought patent claims and lawsuits against brands that may have exploited our patents or our brands without obtaining our permission. From a commercial standpoint, we've also broadened our product portfolio so we can serve the diversifying needs of e-vapor users in China across multiple dimensions, such as flavor availability, price points, and functionality. Our belief remains that these commercial strategies have worked and will keep working to fight the unauthorized compatible cartridges that are in the markets right now. Thanks a lot for your questions.
Analyst
analystThere are a couple of things I'd like to ask. First, as I understand it, an electronic cigarette clinical trial lab was established by us a few weeks back. What's the main reason for doing that, or what benefit could it bring? Then the second one concerns how regulation might affect things. Specifically, what would be the outcome if China tobacco ends up regulating the entire industry?
Sam Tsang
executiveOf course. Many thanks, Louise; great to have you with us. On your initial question, that relates to the labs Chao brought up during the opening remarks. The trial we're running is, in fact, China's first e-vapor clinical trial project for e-vapor products, and it has cleared both ethical and expert reviews and received approval to proceed. Our view is that this laboratory and the research behind it can demonstrate the leading capabilities we hold in scientific research and clinical trials. As an organization, we hold the belief that facts speak louder than words. Our hope is that more clinical trials involving e-vapor products will take place in the years ahead, alongside growing fact-based, science-based communication among various parties. We also hope a growing number of adult smokers will adopt e-vapor products as their harm reduction tobacco alternatives. Now, turning to the second point about regulations; on March 22, the MIIT put out the draft rules concerning e-vapor products. As was noted during the previous earnings call, feedback from us on the proposed revision of the implementation plan has already been submitted. At this moment, there are no updates regarding the regulations, and no fresh implementation details have been rebuilt; the regulatory measures laid out in the announcement have our support, which includes the proposal to regulate the operating activities of the e-vapor industry and to address potential product safety issues of e-vapor products, false advertisement, et cetera; many thanks for your questions.
Sam Tsang
executiveWe appreciate everyone being here with us. Should anything else come to mind, don't hesitate to reach out to the RLX Technologies Investor Relations team — the contact details are on our website — or to TPG Investor Relations. Many thanks.
Operator
operatorThis concludes the conference call. You may now disconnect your line. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete RLX Technology Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to RLX Technology Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in RLX Technology Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.